SNIPR Biome
- Company typePrivate
- Founded2017
- HeadquartersCopenhagen, Denmark
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
SNIPR Biome firmographics
Firmographics- Name
- SNIPR Biome
- Legal name
- SNIPR Biome ApS
- Website
- https://sniprbiome.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
SNIPR Biome industry classification
Industry- Product category
- CRISPR-based antimicrobial therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD)
- akta.pro secondary industries
- Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ), Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)
Keywords
Where SNIPR Biome is headquartered
LocationHeadquarters
- HQ city
- Copenhagen
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
SNIPR Biome business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Revenue model
- Drug Development & Commercialization: As a clinical-stage biotech, SNIPR Biome does not yet generate product revenue. The company is developing a pipeline of CRISPR-based therapeutic candidates (SNIPR001, SNIPR-EED, SNIPR-lung, SNIPR-resensitize, SNIPR004 programs) targeting antimicrobial resistance, cancer, and chronic infections. Future revenue is expected from product sales upon regulatory approval.
- Platform Technology Licensing: SNIPR has opened its CRISPR technology for free use in academic and non-commercial research worldwide, with commercial licenses available for products built on its platform. This non-profit patent licensing program enables the field while preserving commercial licensing rights.
- R&D Partnerships & Co-Development Deals: Strategic R&D partnerships with pharmaceutical companies, patient advocacy foundations, and academic institutions co-developing pipeline assets. Revenue could flow from upfront payments, milestone payments, and royalties under co-development agreements.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
SNIPR Biome product offering
Product offeringCore offering
SNIPR Biome develops CRISPR-based precision antimicrobial therapeutics using two proprietary delivery platforms — CRISPR-armed bacteriophages and CRISPR-armed engineered probiotic bacteria (PicoBiotics). The platform programs CRISPR arrays and Cas enzymes to selectively cut and kill specific DNA sequences in target bacteria, achieving more than 99.9% targeted bacterial kill rates while preserving beneficial microbiota. The lead asset SNIPR001 is being advanced through Phase 1b/2a clinical trials for E. coli bloodstream infection prevention in hematological cancer patients, with additional programs in cystic fibrosis lung infections, environmental enteric dysfunction in pregnant women, and AMR resensitization.
Differentiator
Problem solved
Functional benefit
Products and services
- SNIPR001 (Oral) Oral CRISPR-armed phage cocktail targeting E. coli for prevention of bloodstream infections in immunocompromised hematological cancer patients undergoing hematopoietic stem cell transplantation; currently in Phase 1b/2a clinical trials.
- SNIPR001 (IV) Intravenous formulation of SNIPR001's CRISPR-based therapeutic targeting multidrug-resistant E. coli causing uUTI, sepsis, and post-kidney-transplant infections, co-developed with UC San Diego.
- SNIPR-lung (Phage therapy for cystic fibrosis) CRISPR-armed phage therapy targeting chronic Pseudomonas aeruginosa lung infections in cystic fibrosis patients, supported by the Cystic Fibrosis Foundation.
- SNIPR-EED (Environmental Enteric Dysfunction program) CRISPR-medicines targeting gut E. coli and K. pneumoniae to address environmental enteric dysfunction in pregnant women in low- and middle-income countries, funded by the Bill & Melinda Gates Foundation.
- SNIPR-resensitize (AMR resensitization program) CRISPR-based resensitization program aimed at restoring sensitivity in top WHO/CDC priority AMR pathogens to existing safe and affordable antibiotics, supported by SPRIN-D.
- Non-Profit CRISPR Patent Licensing Program Licensing program allowing academic and non-commercial research use of SNIPR's CRISPR/Cas patent estate without a written license, and commercial licensing for products built on the platform.
Quantifiable outcome
- Up to 78% reduction in E. coli levels at highest dose by day 14 in Phase 1 healthy volunteer trial, with dose-proportional stool recovery and microbiome preservation
- +4 more outcomes
Companies that use SNIPR Biome
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
SNIPR Biome technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
SNIPR Biome partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered supporting and minor.
- UC San DiegosupportingUC San Diego is a collaborator on SNIPR001-IV, the intravenous formulation of SNIPR Biome's CRISPR-based therapeutic targeting MDR E. coli for urinary tract infections, sepsis, and kidney transplant-related infections.
- MD Anderson Cancer CentersupportingMD Anderson Cancer Center is referenced as a collaborator alongside CARB-X and Gates Foundation in supporting SNIPR Biome's clinical development programs, particularly in hematological cancer and oncology-related infections.
- George Church (Harvard Medical School)minorProfessor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and MIT, serving on SNIPR Biome's Scientific Advisory Board. A co-founder of the company and scientific pioneer in synthetic biology and genomics.
- Harris Wang (Columbia University)minorAssistant Professor in Systems Biology at Columbia University Medical Center, serving on SNIPR Biome's Scientific Advisory Board with expertise in synthetic biology and microbiome engineering.
- Peter J. Turnbaugh (UCSF)minorAssociate Professor of Microbiology and Immunology at UCSF School of Medicine, serving on SNIPR Biome's Scientific Advisory Board with expertise in microbiome science and host-microbe interactions.
- Joe Bondy-Denomy (UCSF)minorPrincipal Investigator of the Laboratory of Bacterial Immunology at UCSF, serving on SNIPR Biome's Scientific Advisory Board with expertise in bacteriophage biology and CRISPR systems.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
SNIPR Biome competitors and assessment
Company assessmentDirect peers
- Eligo Bioscience: Paris-based biotech developing CRISPR-based "eligobiotics" delivered via phage to selectively kill or modify bacteria in the microbiome. Closest direct peer to SNIPR's CRISPR-armed phage approach, with overlapping modality (CRISPR-phage) and similar indication focus on microbiome precision editing.
- Locus Biosciences: US biotech developing CRISPR-engineered phage ("crPhage") therapies, including LBP-EC01 in clinical trials for E. coli urinary tract infections. Direct competitor to SNIPR001-IV in the IV/uUTI space and a near-identical CRISPR-phage therapeutic platform.
- Adaptive Phage Therapeutics: US phage therapy company developing personalized phage cocktails against drug-resistant bacterial infections, including for immunocompromised and CF patients. Directly comparable therapeutic modality and indication overlap with SNIPR, though without CRISPR precision layer.
- PhagePro: Boston-based biotech engineering phage cocktails to target enteric pathogens including E. coli in low- and middle-income countries. Closely comparable to SNIPR's EED program targeting gut pathogens, though without CRISPR enhancement.
- Armata Pharmaceuticals: Clinical-stage phage therapy company with multiple programs including Pseudomonas aeruginosa for cystic fibrosis patients (AP-PA02) and Staphylococcus aureus bacteremia. Directly comparable to SNIPR's SNIPR-lung CF program and overall phage therapeutic modality.
Emerging players
- Vedanta Biosciences: Clinical-stage biotech developing defined bacterial consortia to treat infections and immune-mediated diseases, including CDI and AMR-related indications. Comparable as microbiome-modulating therapeutics for infectious disease, but uses live bacterial consortia rather than CRISPR-phage killing.
- BioVersys: Swiss clinical-stage biotech developing small-molecule therapeutics to address antimicrobial resistance, including antibiotic resensitization programs. Comparable to SNIPR's AMR resensitization program (SNIPR-resensitize) in addressing the same priority pathogen list, but uses traditional pharmacology.
- Novome Biotechnologies: US biotech engineering live bacterial therapeutics (genetically modified gut bacteria) for diseases including hyperoxaluria. Highly comparable to SNIPR's PicoBiotics platform using engineered probiotic chassis for therapeutic delivery in the gut.
Broad incumbents
- Seres Therapeutics: Pioneer microbiome therapeutics company with an approved microbiome therapy (VOWST for recurrent C. difficile). Broad microbiome-based pipeline provides a benchmark for commercialization and regulatory precedent relevant to SNIPR's bacterial-based therapeutic approach.
- Ferring Pharmaceuticals: Global pharmaceutical company with significant microbiome and reproductive health portfolio, including approved microbiome-based therapies and major LMIC maternal health programs. Relevant incumbent for SNIPR's CF, AMR, and maternal health (EED) indications, and connected to SNIPR via board member Per Falk.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
SNIPR Biome social profiles
Digital presenceSNIPR Biome financial estimates
Financial estimateRevenue estimate
Valuation estimate
SNIPR Biome leadership team
Management profileNumber of profiles
Profiles15 records
SNIPR Biome funding detail
Funding detailFunding overview
Funding rounds6 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SNIPR Biome M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SNIPR Biome
What does SNIPR Biome do?
SNIPR Biome develops CRISPR-based precision antimicrobial therapeutics using two proprietary delivery platforms — CRISPR-armed bacteriophages and CRISPR-armed engineered probiotic bacteria (PicoBiotics). The platform programs CRISPR arrays and Cas enzymes to selectively cut and kill specific DNA sequences in target bacteria, achieving more than 99.9% targeted bacterial kill rates while preserving beneficial microbiota. The lead asset SNIPR001 is being advanced through Phase 1b/2a clinical trials for E. coli bloodstream infection prevention in hematological cancer patients, with additional programs in cystic fibrosis lung infections, environmental enteric dysfunction in pregnant women, and AMR resensitization.
Is SNIPR Biome a public or private company?
SNIPR Biome is a private company. It is classified as venture growth investor backed and is currently operating.
When was SNIPR Biome founded?
SNIPR Biome was founded in 2017. It employs 11 to 50 people.
Where is SNIPR Biome based?
SNIPR Biome is headquartered in Copenhagen, Denmark, in the Europe region.
How does SNIPR Biome make money?
Three revenue lines are on record. Drug Development & Commercialization is the primary driver. The others are platform Technology Licensing and R&D Partnerships & Co-Development Deals.
Who are SNIPR Biome's main competitors?
Direct peers on record are Eligo Bioscience, Locus Biosciences, Adaptive Phage Therapeutics, PhagePro and Armata Pharmaceuticals. Emerging players are Vedanta Biosciences, BioVersys and Novome Biotechnologies. Broad incumbents are Seres Therapeutics and Ferring Pharmaceuticals.
Does SNIPR Biome have an API?
No public API is recorded for SNIPR Biome.
What industry is SNIPR Biome in?
SNIPR Biome's product category is CRISPR-based antimicrobial therapeutics. Its primary akta.pro industry code is HLAAAFAD, Engineered Microbial Therapeutics (synthetic biology, gene circuits), with a secondary code of HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 541714 and its SIC code is 2836.